MSA
SUPN icon

Mason Street Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Mason Street Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,646
Closed -$494K – 1087
2020
Q4 		$494K Sell
19,646
-112
-0.6% -$2.41K 0.01% 1174
2020
Q3 		$412K Buy
19,758
+33
+0.2% +$749 0.01% 1148
2020
Q2 		$468K Buy
19,725
+1,452
+8% +$32.1K 0.01% 1106
2020
Q1 		$329K Hold
18,273
– – 0.01% 1130
2019
Q4 		$433K Buy
18,273
+464
+3% +$11.3K 0.01% 1182
2019
Q3 		$489K Buy
17,809
+323
+2% +$9.57K 0.01% 1108
2019
Q2 		$579K Buy
17,486
+683
+4% +$23.4K 0.01% 1044
2019
Q1 		$589K Buy
16,803
+575
+4% +$21.4K 0.01% 1080
2018
Q4 		$539K Buy
16,228
+757
+5% +$32.6K 0.01% 1013
2018
Q3 		$779K Buy
15,471
+514
+3% +$25.4K 0.02% 960
2018
Q2 		$895K Buy
14,957
+660
+5% +$34.2K 0.02% 902
2018
Q1 		$655K Buy
14,297
+964
+7% +$40.2K 0.02% 956
2017
Q4 		$531K Buy
13,333
+493
+4% +$19.5K 0.01% 1008
2017
Q3 		$514K Buy
12,840
+440
+4% +$19K 0.01% 1009
2017
Q2 		$534K Buy
12,400
+680
+6% +$24.2K 0.01% 982
2017
Q1 		$367K Buy
11,720
+902
+8% +$24.2K 0.01% 1071
2016
Q4 		$273K Buy
10,818
+626
+6% +$14K 0.01% 1145
2016
Q3 		$252K Buy
10,192
+3,429
+51% +$77.6K 0.01% 1129
2016
Q2 		$138K Buy
6,763
+675
+11% +$12K ﹤0.01% 1294
2016
Q1 		$93K Buy
6,088
+568
+10% +$7.41K ﹤0.01% 1357
2015
Q4 		$74K Buy
5,520
+524
+10% +$8.11K ﹤0.01% 1379
2015
Q3 		$70K Buy
4,996
+1,037
+26% +$19.3K ﹤0.01% 1369
2015
Q2 		$67K Buy
+3,959
New +$56.3K ﹤0.01% 1399

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Mason Street Advisors's SUPN Position: Q1 2021 in Review

Mason Street Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2021, closing a stake of 19,646 shares — an estimated $494K sold.

Mason Street Advisors first reported a position in SUPN in Q2 2015 and held it in 23 quarters. The position peaked at $895K in Q2 2018. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • Mason Street Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 19,646 Supernus Pharmaceuticals shares in Q1 2021, an estimated $494K.
  • Mason Street Advisors first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 23 quarters.
  • Mason Street Advisors's Supernus Pharmaceuticals position peaked at $895K in Q2 2018.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.